A systematic review and meta-analysis of randomized controlled trials of the effect of konjac glucomannan, a viscous soluble fiber, on LDL cholesterol and the new lipid targets non-HDL cholesterol and apolipoprotein B
Ho HVT, Jovanovski E, Zurbau A, Blanco Mejia S, Sievenpiper JL, Au-Yeung F, Jenkins AL, Duvnjak L, Leiter L, Vuksan V
The American journal of clinical nutrition · 70 citas
Cómo se estudió
- Diseño
- Metaanálisis (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
- Consumo medido con
- No se indica
Quién lo pagó
- Financiación
- Financiación independiente
- Organización sin fines de lucro
- Physicians' Services Incorporated Foundation
- Gobierno
- Canadian Institutes of Health Research
Según 2 financiadores declarados.
Publicación
- Publicado
- 2017-03-30 · Am J Clin Nutr · vol. 105 · número 5 · págs. 1239–1247
- Editorial
- Elsevier BV
- Citado
- 111 citas · más que el 88% de estudios similares · 2.2× el promedio de su campo
- Referencias
- 45 trabajos
- Acceso
- Lectura gratuita
- Áreas de investigación
- Lipoproteins and Cardiovascular Health · Food composition and properties · Natural Products and Biological Research
- Palabras clave
- konjac glucomannan, LDL cholesterol, non-HDL cholesterol, apolipoprotein B, cholesterol-lowering effect, cardiovascular risk, dietary fiber supplementation, lipid metabolism
- MeSH
- humans, amorphophallus, cardiovascular diseases, cholesterol, mannans, apolipoproteins b, anticholesteremic agents, diet, dietary fiber, adult, middle aged, child, female, male, cholesterol, ldl, cholesterol, hdl
10 autores
- Hoang Vi Thanh Ho🇨🇦University of Toronto
- Elena Jovanovski🇨🇦University of Toronto
- Andreea Zurbau🇨🇦University of Toronto
- Sonia Blanco Mejía🇨🇦St. Michael's Hospital; University of Toronto
- John L. Sievenpiper🇨🇦🇨🇳St. Michael's Hospital; University of Toronto; Li Ka Shing Foundation
- Fei Au‐Yeung🇨🇦University of Toronto
- Alexandra L. Jenkins
- Lea Smircic Duvnjak🇭🇷University of Zagreb; Klinička bolnica Merkur
- Lawrence A. Leiter🇨🇦🇨🇳University of Toronto; Li Ka Shing Foundation
- Vladimir V.V. Vuksan🇨🇦 · autor de correspondenciaUniversity of Toronto
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background: Evidence from randomized controlled trials (RCTs) suggests the consumption of konjac glucomannan (KJM), a viscous soluble fiber, for improving LDL-cholesterol concentrations. It has also been suggested that the cholesterol-lowering potential of KJM may be greater than that of other fibers. However, trials have been relatively scarce and limited in sample size and duration, and the effect estimates have been inconsistent. The effect of KJM on new lipid targets of cardiovascular disease (CVD) risk is also unknown.Objective: This systematic review and meta-analysis aimed to assess the effect of KJM on LDL cholesterol, non-HDL cholesterol, and apolipoprotein B.Design: Medline, Embase, CINAHL, and the Cochrane Central databases were searched. We included RCTs with a follow-up of ≥3 wk that assessed the effect of KJM on LDL cholesterol, non-HDL cholesterol, or apolipoprotein B. Data were pooled by using the generic inverse-variance method with random-effects models and expressed as mean differences (MDs) with 95% CIs. Heterogeneity was assessed by the Cochran Q statistic and quantified by the I2 statistic.Results: Twelve studies (n = 370), 8 in adults and 4 in children, met the inclusion criteria. KJM significantly lowered LDL cholesterol (MD: -0.35 mmol/L; 95% CI: -0.46, -0.25 mmol/L) and non-HDL cholesterol (MD: -0.32 mmol/L; 95% CI: -0.46, -0.19 mmol/L). Data from 6 trials suggested no impact of KJM on apolipoprotein B.Conclusions: Our findings support the intake of ∼3 g KJM/d for reductions in LDL cholesterol and non-HDL cholesterol of 10% and 7%, respectively. The information may be of interest to health agencies in crafting future dietary recommendations related to reduction in CVD risk. This study was registered at clinicaltrials.gov as NCT02068248.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.